Prolonged reversal of the phencyclidine-induced impairment in novel object recognition by a serotonin (5-HT)1A-dependent mechanism

Behavioural Brain Research
M HoriguchiH Y Meltzer


Many acute treatments transiently reverse the deficit in novel object recognition (NOR) produced by subchronic treatment with the N-methyl-d-aspartate receptor non-competitive antagonist, phencyclidine (PCP), in rodents. Treatments which restore NOR for prolonged periods after subchronic PCP treatment may have greater relevance for treating the cognitive impairment in schizophrenia than those which restore NOR transiently. We examined the ability of post-PCP subchronic lurasidone, an atypical APD with potent serotonin (5-HT)1A partial agonism and subchronic tandospirone, a selective 5-HT1A partial agonist, to enable prolonged reversal of the subchronic PCP-induced NOR deficit. Rats treated with subchronic PCP (2mg/kg, twice daily for 7 days) or vehicle, followed by a 7day washout period were subsequently administered lurasidone or tandospirone twice daily for 7 days (day 15-21), and tested for NOR weekly for up to two additional weeks. Subchronic lurasidone (1, but not 0.1mg/kg) or tandospirone (5, but not 0.6mg/kg) significantly reversed the PCP-induced NOR deficit at 24h and 7days after the last injection, respectively. The effect of lurasidone persisted for one more week (day 36, 14 days after the last lurasidone dose), whil...Continue Reading


Oct 1, 1991·The American Journal of Psychiatry·D C Javitt, S R Zukin
Jul 1, 1991·Archives of General Psychiatry·A J SaykinP Stafiniak
Jun 1, 2000·Journal of Clinical Psychopharmacology·Tomiki SumiyoshiH Y Meltzer
May 10, 2001·Biological Psychiatry·Tomiki SumiyoshiH Y Meltzer
Oct 2, 2001·The American Journal of Psychiatry·T SumiyoshiH Y Meltzer
Jan 19, 2005·Naunyn-Schmiedeberg's Archives of Pharmacology·Nicole R SullivanLouis D Van de Kar
Mar 24, 2005·The International Journal of Neuropsychopharmacology·Neil D WoodwardDavid H Zald
Jan 13, 2006·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Kyoko NishitsujiShun Higuchi
Jun 15, 2006·Cellular and Molecular Neurobiology·Joseph T Coyle
Jun 6, 2007·Archives of General Psychiatry·Richard S E KeefeNeurocognitive Working Group
Jan 1, 2008·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Hiroko HagiwaraKenji Hashimoto
Aug 16, 2008·Brain Research Reviews·Handan Gunduz-Bruce
Aug 19, 2008·Behavioural Brain Research·H Y Meltzer, Tomiki Sumiyoshi
May 21, 2009·Journal of Molecular Neuroscience : MN·Yong Kee ChoiFrank I Tarazi
Sep 9, 2009·The European Journal of Neuroscience·Thomas Klausberger
Sep 29, 2009·Expert Opinion on Investigational Drugs·Jonathan M MeyerEdward Schweizer
Apr 21, 2010·The Journal of Pharmacology and Experimental Therapeutics·Tadashi IshibashiMitsutaka Nakamura
May 12, 2011·The Journal of Pharmacology and Experimental Therapeutics·M HoriguchiH Y Meltzer
Jun 17, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·John D ElsworthRobert H Roth
Jul 8, 2011·The International Journal of Neuropsychopharmacology·John D ElsworthRobert H Roth
Aug 16, 2011·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Kyeong-Ryoon LeeTae-Sung Koo

Related Concepts

Neuro-Oncological Ventral Antigen 2
Toxicity Tests, Subchronic
Cortex Bone Disorders
Adrenal Cortex Diseases
Neurologic Manifestations
Assay OF Haloperidol

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Barrel cortex

Here is the latest research on barrel cortex, a region of somatosensory and motor corticies in the brain, which are used by animals that rely on whiskers for world exploration.